Prevymis (letermovir) - Merck (MSD)
Letermovir does not affect long-term polyclonal immune reconstitution after allogeneic hematopoietic stem cell transplantation with ATG-based GvHD prophylaxis. (PubMed, Front Immunol) - Jun 9, 2026 - "Distinct immune dynamics were observed in the LET cohort, including lower early CD8+ T-cell counts and earlier NK-cell expansion peak. Despite these differences, LET does not appear to influence the long-term incidence and composition of IR." 
Journal • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation • CD4 • CD8 • NCAM1
http://www.ncbi.nlm.nih.gov/pubmed/42253961
 
Adela Maria Neagoie; Axel Benner; Christian Sinzger; Conrad Weidt; Daniel Fürst; Detlef Michel; Donald Bunjes; Elisa Sala; Frank Stegelmann; Hartmut Döhner; Jacqueline Schnell; Katharina Göhring; Katrin Strauss; Maral Saadati; Michaela Feuring; Thomas Stamminger; Verena Wais
 
Jun 9, 2026
 
Prev Next